Forbes censors Peter Lipson “Speech is best countered by more speech” article comments

Forbes (#Forbes) removed comments that were posted on the Peter Lipson (@palMD) article where he proclaimed:

“Speech is best countered by more speech”
http://t.co/8PjEPukjpP

http://www.forbes.com/sites/peterlipson/2013/04/19/a-film-producer-a-cancer-doctor-and-their-critics
PalMD (@palmd) tweeted at 9:12am – 20 Apr 13:

This happened after David H. Gorski

(@gorskon @oracknows, @ScienceBasedMed http://www.scienceblogs.com/Insolence http://www.sciencebasedmedicine.org #sciencebasedmed)

revealed on Twitter that Peter Lipson was his “bud” and Guy Chapman

(@SceptiGuy http://www.chapmancentral.co.uk
@vGuyUK
http://www.chapmancentral.co.uk/blahg)

mentioned Gorski on Peter Lipson’s article, and I posted Gorski’s “pal” status with Lipson on the article (see near bottom of this blog, in bold), after which ALL of my comments on the article were removed

Guy Chapman is best known for:
anarchic_teapot (@anarchic_teapot) tweeted at 5:24am – 15 Jun 12:
Cunts are nice things. He’s a malodorous arsehole & profiteering shite RT @SceptiGuy: Is Stanislaw Burzynski a cunt?
http://t.co/8bmXEJ7l

David Gorski (@gorskon) tweeted at 3:58pm – 20 Apr 13:
http://t.co/ollMCNBukK

TheSkeptiCritic (@TheSkeptiCritic) tweeted at 12:14am – 21 Apr 13:
http://t.co/WjjtQvtD1d
“@gorskon: pro-#Burzynski
on my bud Peter’s post
Tactical air support
forbes.com/sites/peterlip…”
#Forbes
“The Skeptics” need “help”!!
I provide—
(@TheSkeptiCritic) April 21, 2013

TheSkeptiCritic (@TheSkeptiCritic) tweeted at 1:47pm – 21 Apr 13:
http://t.co/WjjtQvtD1d
“@IDoubtIt: @gorskon pro #Burzynski
descended
Peter’s post
Tactical air support forbes.com/sites/peterlip…”

“The Skeptics”need”HELP”
I provide—
(@TheSkeptiCritic) April 21, 2013

TheSkeptiCritic (@TheSkeptiCritic) tweeted at 2:28am – 22 Apr 13:
“@gorskon: @rjblaskiewicz #Burzynski trolls are in trouble now…”
#Forbes
Now we find out if your”pal”Peter Lipson walks the walk►”Speech”!—
(@TheSkeptiCritic) April 22, 2013

TheSkeptiCritic (@TheSkeptiCritic) tweeted at 11:41am – 20 Apr 13:
→http://t.co/8nuBkviWWF

https://t.co/XYy7rjlCAi

›Peter Lipson
»A Film Producer, A Cancer Doctor, And Their Critics – Forbes

→ onforb.es/11pwse9
#Burzynski←
► …anislawrajmundburzynski.wordpress.com/2013/04/20/a-f…—
(@TheSkeptiCritic) April 20, 2013

TheSkeptiCritic (@TheSkeptiCritic) tweeted at 11:52am – 20 Apr 13:
http://t.co/WjjtQvtD1d
“@palmd: Didnt take long for the #Burzynski trolls to show up
forbes.com/sites/peterlip…”

Didn’t take long for”The Skeptics”to show up
#Forbes—
(@TheSkeptiCritic) April 20, 2013

TheSkeptiCritic (@TheSkeptiCritic) tweeted at 2:34pm – 20 Apr 13:
http://t.co/WjjtQvtD1d

►https://t.co/XYy7rjlCAi
“@medtek: Congratulations Eric!
› forbes.com/sites/peterlip…”
“The Sheeple”↓Barbara Streisand
» #Forbes «
→#Burzynski

► …anislawrajmundburzynski.wordpress.com/2013/04/20/a-f…—
(@TheSkeptiCritic) April 20, 2013

TheSkeptiCritic (@TheSkeptiCritic) tweeted at 4:50pm – 20 Apr 13:
http://t.co/vh3cgAR6hW

https://t.co/XYy7rjlCAi
“@palmd: Didnt take long for
#Burzynski trolls to show up
forbes.com/sites/peterlip…”
#Forbes
Look it’s ►”The Skeptics”!

…anislawrajmundburzynski.wordpress.com/2013/04/20/a-f…—
(@TheSkeptiCritic) April 20, 2013

TheSkeptiCritic (@TheSkeptiCritic) tweeted at 3:49pm – 21 Apr 13:
http://t.co/vh3cgAR6hW
#Forbes Peter Lipson #Burzynski article proclaims:”Speech is best countered by more speech”
forbes.com/sites/peterlip…

@BurzynskiMovie
#EPIC—
(@TheSkeptiCritic) April 21, 2013

TheSkeptiCritic (@TheSkeptiCritic) tweeted at 4:03pm – 21 Apr 13:
http://t.co/vh3cgAR6hW

Is #Forbes Peter Lipson #Burzynski article trying to invoke #Burzynski critics “Streisand effect”?
forbes.com/sites/peterlip…

@BurzynskiMovie—
(@TheSkeptiCritic) April 21, 2013

TheSkeptiCritic (@TheSkeptiCritic) tweeted at 3:04am – 22 Apr 13:
http://t.co/vh3cgAR6hW
Peter Lipson #Burzynski article comment screenpics re”Speech is best countered by more speech”
#Forbes walk the walk?

forbes.com/sites/peterlip…—
(@TheSkeptiCritic) April 22, 2013

TheSkeptiCritic (@TheSkeptiCritic) tweeted at 11:38am – 22 Apr 13:
http://t.co/BaZ3aHXvUh
“@neilthackray: #burzynski
One more crack at asking
open question
http://t.co/BaZ3aHXvUh"
Read #Forbes Peter Lipson article
@BurzynskiMovie—
(@TheSkeptiCritic) April 22, 2013

4/19/2013 @ 9:43PM |2,351 views
A Film Producer, A Cancer Doctor, And Their Critics
Comment Now Following Comments

Thank you for submitting your comment:

Mr. Morgan, I am not sure how you are obtaining your clinical trial data for Burzynski, since a simple review shows that:
http://clinicaltrials.gov/ct2/results?term=antineoplaston&Search=Search
differs from what the National Cancer Institute (NCI) at the National Institutes of Health (NIH) has when you follow the links on
http://www.clinicaltrials.gov
which is supposedly sourced from the NCI data:
61 TOTAL
1 – Not Yet Recruiting (Open)(Phase 3)
1 – Closed
2 – Terminated (Withdrawn due to slow enrollment)
7 – Withdrawn (This study has been withdrawn prior to enrollment)
10 – Recruiting (Open)
11 – Open (1 Not Yet Recruiting / 10 Recruiting)
40 – Active, not recruiting (Closed)
http://cancer.gov/clinicaltrials/search/results?protocolsearchid=11475951

http://cancer.gov/clinicaltrials/search/results?protocolsearchid
With the data being different between the 2 sources, how are we supposed to know what is correct?

Please note: Your comment will be reviewed by Forbes staff before appearing on the site.

Share your comment:
facebook
linkedin
twitter

Thank you for submitting your comment:

New comments typically appear within 30 seconds.

Mr. Chapman, you commented:
“PDJT aka “Astroturfwatch””
You clearly seem to have me confused with someone else
I am NOT “Astroturfwatch”
I am NOT Eric Merola
What I AM is an American who asks the questions which those of you blogging in the UK, and those elsewhere, do NOT seem to want to address
Peter Lipson: “Speech is best countered by more speech”

Share your comment:
facebook
linkedin
twitter

Thank you for submitting your comment:

New comments typically appear within 30 seconds.

Mr. Morgan, I am not sure how you are obtaining your clinical trial data for Burzynski, since a simple review of your link differs from what the National Cancer Institute (NCI) at the National Institutes of Health (NIH) has when you follow the links on Clinical Trials . gov, which is supposedly sourced from the NCI data:
61 TOTAL
1 – Not Yet Recruiting (Open)(Phase 3)
1 – Closed
2 – Terminated (Withdrawn due to slow enrollment)
7 – Withdrawn (This study has been withdrawn prior to enrollment)
10 – Recruiting (Open)
11 – Open (1 Not Yet Recruiting / 10 Recruiting)
40 – Active, not recruiting (Closed)
http://cancer.gov/clinicaltrials/search/results?protocolsearchid=11475951
With the data being different between the 2 sources, how are we supposed to know what is correct?
Peter Lipson: “Speech is best countered by more speech”

Share your comment:
facebook
linkedin
twitter

Thank you for submitting your comment:

New comments typically appear within 30 seconds.

Mr. Ogon, I’m not exactly who you were replying to, but you refer to a “25% cure rate,” and in the below 2 studies, neither one mentions a “25% cure rate” in it:
“You mean PMIDs 12718563 and 16484713? (These, at least, are the ones that Merola cites, which I assume is the sum total of your “fact checking.”)”
You then go on to comment:
“(2) it’s essentially the same group in both”
However, the dosages in the 2 studies are different, so I am not certain how you came to the above conclusion
Peter Lipson: “Speech is best countered by more speech”

Share your comment:
facebook
linkedin
twitter

Submit Comment
Forbes writers have the ability to call out member comments they find particularly interesting. Called-out comments are highlighted across the Forbes network. You’ll be notified if your comment is called out.

4/19/2013 @ 9:43PM |2,372 views
A Film Producer, A Cancer Doctor, And Their Critics
Comment Now Following Comments

Comments
Called-Out
EXPAND ALL COMMENTS
– collapse comments

Didymus Thomas 3 hours ago
Mr. Chapman, you commented:
” … the failure to publish any usable results from any single trial is grossly unethical”
“ The FDA’s Drug Review Process: Ensuring Drugs Are Safe and Effective” advises:
“[T]he emphasis in Phase 2 is on EFFECTIVENESS”
“This phase aims to obtain PRELIMINARY DATA on whether the drug works in people who have a certain disease or condition”
“Phase 3 studies begin if EVIDENCE of EFFECTIVENESS is shown in Phase 2″
“These studies gather more information about safety and EFFECTIVENESS, studying different populations and different dosages and using the drug in combination with other drugs”
I have already previously addressed the issue of publication re comments made by Mr. Ogon, before you made your most recent comment concerning the same subject.
Please see my reply to him.

Once you have done that, please advise how your ” … the failure to publish any usable results from any single trial is grossly unethical,” comment is relevant.
What is the relevance of publishing results of phase 2 clinical trials if it is only “ PRELIMINARY DATA,” and NOT waiting until phase 3 study which would “gather more information about safety and EFFECTIVENESS”?
http://www.fda.gov/drugs/resourcesforyou/consumers/ucm143534.htm
Reply

Didymus Thomas 1 hour ago
Mr. Morgan, here is the other NCI link:
http://cancer.gov/clinicaltrials/search/results?protocolsearchid=11476036
Reply

randy hinton 1 hour ago

Reply

Didymus Thomas 1 hour ago
Mr. Chapman, you commented:
“PDJT aka “Astroturfwatch””
You clearly seem to have me confused with someone else
I am NOT “Astroturfwatch”
I am NOT Eric Merola
What I AM is an American who asks the questions which those of you blogging in the UK, and those elsewhere, do NOT seem to want to address
Peter Lipson: “Speech is best countered by more speech”
Reply

Didymus Thomas 1 hour ago
Mr. Morgan, I am not sure how you are obtaining your clinical trial data for Burzynski, since a simple review of your link differs from what the National Cancer Institute (NCI) at the National Institutes of Health (NIH) has when you follow the links on Clinical Trials . gov, which is supposedly sourced from the NCI data:
61 TOTAL
1 – Not Yet Recruiting (Open)(Phase 3)
1 – Closed
2 – Terminated (Withdrawn due to slow enrollment)
7 – Withdrawn (This study has been withdrawn prior to enrollment)
10 – Recruiting (Open)
11 – Open (1 Not Yet Recruiting / 10 Recruiting)
40 – Active, not recruiting (Closed)
http://cancer.gov/clinicaltrials/search/results?protocolsearchid=11475951
With the data being different between the 2 sources, how are we supposed to know what is correct?
Peter Lipson: “Speech is best countered by more speech”
Reply

Didymus Thomas 10 minutes ago
Mr. Ogon, I’m not exactly who you were replying to, but you refer to a “25% cure rate,” and in the below 2 studies, neither one mentions a “25% cure rate” in it:
“You mean PMIDs 12718563 and 16484713? (These, at least, are the ones that Merola cites, which I assume is the sum total of your “fact checking.”)”
You then go on to comment:
“(2) it’s essentially the same group in both”
However, the dosages in the 2 studies are different, so I am not certain how you came to the above conclusion
Peter Lipson: “Speech is best countered by more speech”
Reply

4/19/2013 @ 9:43PM |2,377 views
A Film Producer, A Cancer Doctor, And Their Critics
Comment Now Following Comments

Thank you for submitting your comment:

New comments typically appear within 30 seconds.

FW and Mr. Ogon, I contacted the National Cancer Institute (NCI) at the National Institutes of Health (NIH) earlier this year and was advised:
“Not every cancer clinical trial taking place in the United States is listed on our NCI clinical trials database”
Peter Lipson: “Speech is best countered by more speech”

Share your comment:
facebook
linkedin
twitter

Thank you for submitting your comment:

New comments typically appear within 30 seconds.

Mr. Ogon, why is “HYPERNATREMIA” and “SEIZURES” NOT listed on the National Cancer Institute (NCI) at the National Institutes of Health (NIH) list of ADVERSE EFFECTS for antineoplastons?
http://www.cancer.gov/cancertopics/pdq/cam/antineoplastons/healthprofessional/page6
Peter Lipson: “Speech is best countered by more speech”

Share your comment:
facebook
linkedin
twitter

Thank you for submitting your comment:

New comments typically appear within 30 seconds.

Mr. Ogon, you made various comments re clinical trials, impact factors, etc.
Why should anyone care about your comments when the “National Cancer Institute (NCI) at the National Institutes of Health (NIH), Cancer Clinical Trials, 15. What happens when a clinical trial is over?,” advises:
“The results of clinical trials are OFTEN published in peer-reviewed scientific journals”
” … WHETHER OR NOT the results are published in a peer-reviewed scientific journal … ”
http://m.cancer.gov/topics/factsheets/clinical-trials
This makes it clear that clinical trial results “are OFTEN” published, but sometimes they are “NOT” published “in a peer-reviewed scientific journal”
Peter Lipson: “Speech is best countered by more speech”

Share your comment:
facebook
linkedin
twitter

Thank you for submitting your comment:

New comments typically appear within 30 seconds.

Mr. Ogon, you commented:
“One further has to take into account the fact that Scamley has been known to employ idiosyncratic definitions, such as classifying tumor *growth* as “STABLE DISEASE” for “less than 50% reduction in size but no more than 50% increase in size of the tumor mass, lasting for at least twelve weeks.””
Why should anyone care about your comment re “STABLE DISEASE,” when the FDA has advised:
5/2007 – “Guidance for Industry – Food and Drug Administration”
“Clinical Trial Endpoints for the Approval of Cancer Drugs and Biologics”
“”STABLE DISEASE should not be a component of ORR”
“STABLE DISEASE can reflect the natural history of disease””
(Pg. 10 of 22 = actual pg. 7 of PDF)
“…STABLE DISEASE can be more accurately assessed by TTP or PFS analysis (see below)”
“Also, STABLE DISEASE can be more accurately assessed by TTP or PFS analysis (see below)”
(Pg. 11 of 22 = actual pg. 8 of PDF)
“Time to Progression and Progression-Free Survival”
“TTP – Time to Progression”
“PFS – Progression-Free Survival”
“TTP and PFS have served as primary endpoints for drug approval”
(Pg. 11 of 22 = actual pg. 8 of PDF)
http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm071590.pdf
And in addition, the below 2005 non-Burzynski study also uses “STABLE DISEASE?”
Role of temozolomide after radiotherapy for newly diagnosed diffuse brainstem glioma in children
Results of a multiinstitutional study (SJHG-98)
http://www.ncbi.nlm.nih.gov/m/pubmed/15565574
Peter Lipson: “Speech is best countered by more speech”

Share your comment:
facebook
linkedin
twitter

4/19/2013 @ 9:43PM |2,386 views
A Film Producer, A Cancer Doctor, And Their Critics
Comment Now Following Comments

Thank you for submitting your comment:

New comments typically appear within 30 seconds.

Mr. Chapman, where does the Declaration of Helsinki indicate WHEN human clinical trials results MUST be published?
I do NOT see it listed on the National Institutes of Health, Helsinki document:
http://history.nih.gov/research/downloads/helsinki.pdf
Peter Lipson: “Speech is best countered by more speech”

Share your comment:
facebook
linkedin
twitter

4/19/2013 @ 9:43PM |2,396 views
A Film Producer, A Cancer Doctor, And Their Critics
Comment Now Following Comments

Thank you for submitting your comment:

New comments typically appear within 30 seconds.

Mr. Morgan, is this the Kurume Japanese case study you are referring to?
RANDOMIZED PHASE II STUDY of Hepatic Arterial Infusion with or without ANTINEOPLASTONS as Adjuvant Therapy after Hepatectomy for liver Metastases from Colorectal Cancer
http://www.colorectal-cancer.ca/IMG/pdf/CCAC_Research_June_19_2009.pdf
Annals of Oncology 2010;21:viii221
Game Over?
Peter Lipson: “Speech is best countered by more speech”

Share your comment:
facebook
linkedin
twitter

Thank you for submitting your comment:

New comments typically appear within 30 seconds.

Mr. Ogon, you commented:
“You are right now having a live “debate” in front of more than 10,000 people … ”
I checked the “views” of this article and it was only 2,420 views
Please advise when the “live “debate” in front of more than 10,000 people,” will occur
Peter Lipson: “Speech is best countered by more speech”

Share your comment:
facebook
linkedin
twitter

Mr. Ogon, you commented:
“One further has to take into account the fact that Scamley has been known to employ idiosyncratic definitions, such as classifying tumor *growth* as “STABLE DISEASE” for “less than 50% reduction in size but no more than 50% increase in size of the tumor mass, lasting for at least twelve weeks.””
Why should anyone care about your comment re “STABLE DISEASE,” when the FDA has advised:
5/2007 – “Guidance for Industry – Food and Drug Administration”
“Clinical Trial Endpoints for the Approval of Cancer Drugs and Biologics”
“”STABLE DISEASE should not be a component of ORR”
“STABLE DISEASE can reflect the natural history of disease””
(Pg. 10 of 22 = actual pg. 7 of PDF)
“…STABLE DISEASE can be more accurately assessed by TTP or PFS analysis (see below)”
“Also, STABLE DISEASE can be more accurately assessed by TTP or PFS analysis (see below)”
(Pg. 11 of 22 = actual pg. 8 of PDF)
“Time to Progression and Progression-Free Survival”
“TTP – Time to Progression”
“PFS – Progression-Free Survival”
“TTP and PFS have served as primary endpoints for drug approval”
(Pg. 11 of 22 = actual pg. 8 of PDF)
http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm071590.pdf
And in addition, the below 2005 non-Burzynski study also uses “STABLE DISEASE?”
Role of temozolomide after radiotherapy for newly diagnosed diffuse brainstem glioma in children
Results of a multiinstitutional study (SJHG-98)
http://www.ncbi.nlm.nih.gov/m/pubmed/15565574
Peter Lipson: “Speech is best countered by more speech”
Reply

Didymus Thomas 51 minutes ago
Mr. Chapman, where does the Declaration of Helsinki indicate WHEN human clinical trials results MUST be published?
I do NOT see it listed on the National Institutes of Health, Helsinki document:
http://history.nih.gov/research/downloads/helsinki.pdf
Peter Lipson: “Speech is best countered by more speech”
Reply

Didymus Thomas 30 minutes ago
Mr. Morgan, is this the Kurume Japanese case study you are referring to?
RANDOMIZED PHASE II STUDY of Hepatic Arterial Infusion with or without ANTINEOPLASTONS as Adjuvant Therapy after Hepatectomy for liver Metastases from Colorectal Cancer
http://www.colorectal-cancer.ca/IMG/pdf/CCAC_Research_June_19_2009.pdf
Annals of Oncology 2010;21:viii221
Game Over?
Peter Lipson: “Speech is best countered by more speech”
Reply

Didymus Thomas 3 minutes ago
Mr. Ogon, you commented:
“You are right now having a live “debate” in front of more than 10,000 people … ”
I checked the “
views” of this article and it was only 2,420 views
Please advise when the “live “debate” in front of more than 10,000 people,” will occur
Peter Lipson: “Speech is best countered by more speech”
Reply

Comments
Called-Out
Expand All Comments
– collapse comments

Didymus Thomas 1 hour ago
Mr. Ogon, you commented:
“One further has to take into account the fact that Scamley has been known to employ idiosyncratic definitions, such as classifying tumor *growth* as “STABLE DISEASE” for “less than 50% reduction in size but no more than 50% increase in size of the tumor mass, lasting for at least twelve weeks.””
Why should anyone care about your comment re “STABLE DISEASE,” when the FDA has advised:
5/2007 – “Guidance for Industry – Food and Drug Administration”
“Clinical Trial Endpoints for the Approval of Cancer Drugs and Biologics”
“”STABLE DISEASE should not be a component of ORR”
“STABLE DISEASE can reflect the natural history of disease””
(Pg. 10 of 22 = actual pg. 7 of PDF)
“…STABLE DISEASE can be more accurately assessed by TTP or PFS analysis (see below)”
“Also, STABLE DISEASE can be more accurately assessed by TTP or PFS analysis (see below)”
(Pg. 11 of 22 = actual pg. 8 of PDF)
“Time to Progression and Progression-Free Survival”
“TTP – Time to Progression”
“PFS – Progression-Free Survival”
“TTP and PFS have served as primary endpoints for drug approval”
(Pg. 11 of 22 = actual pg. 8 of PDF)
http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm071590.pdf
And in addition, the below 2005 non-Burzynski study also uses “STABLE DISEASE?”
Role of temozolomide after radiotherapy for newly diagnosed diffuse brainstem glioma in children
Results of a multiinstitutional study (SJHG-98)
http://www.ncbi.nlm.nih.gov/m/pubmed/15565574
Peter Lipson: “Speech is best countered by more speech”

Didymus Thomas 1 hour ago
Mr. Chapman, where does the Declaration of Helsinki indicate WHEN human clinical trials results MUST be published?
I do NOT see it listed on the National Institutes of Health, Helsinki document:
http://history.nih.gov/research/downloads/helsinki.pdf
Peter Lipson: “Speech is best countered by more speech”

Didymus Thomas 45 minutes ago
Mr. Morgan, is this the Kurume Japanese case study you are referring to?
RANDOMIZED PHASE II STUDY of Hepatic Arterial Infusion with or without ANTINEOPLASTONS as Adjuvant Therapy after Hepatectomy for liver Metastases from Colorectal Cancer
http://www.colorectal-cancer.ca/IMG/pdf/CCAC_Research_June_19_2009.pdf
Annals of Oncology 2010;21:viii221
Game Over?
Peter Lipson: “Speech is best countered by more speech”

Didymus Thomas 18 minutes ago
Mr. Ogon, you commented:
“You are right now having a live “debate” in front of more than 10,000 people … ”
I checked the “
views” of this article and it was only 2,420 views
Please advise when the “live “debate” in front of more than 10,000 people,” will occur
Peter Lipson: “Speech is best countered by more speech”

Thank you for submitting your comment:

New comments typically appear within 30 seconds.

Mr. Ogon, you made various comments re clinical trials, impact factors, etc.
Why should anyone care about your comments when the “National Cancer Institute (NCI) at the National Institutes of Health (NIH), Cancer Clinical Trials, 15. What happens when a clinical trial is over?,” advises:
“The results of clinical trials are OFTEN published in peer-reviewed scientific journals”
” … WHETHER OR NOT the results are published in a peer-reviewed scientific journal … ”
This makes it clear that clinical trial results “are OFTEN” published, but sometimes they are “NOT” published “in a peer-reviewed scientific journal”
Peter Lipson: “Speech is best countered by more speech”

Submit Comment
Forbes writers have the ability to call out member comments they find particularly interesting. Called-out comments are highlighted across the Forbes network. You’ll be notified if your comment is called out.

Comments
Called-Out
EXPAND ALL COMMENTS
– collapse comments

Didymus Thomas 3 hours ago
Mr. Ogon, you commented:
“One further has to take into account the fact that Scamley has been known to employ idiosyncratic definitions, such as classifying tumor *growth* as “STABLE DISEASE” for “less than 50% reduction in size but no more than 50% increase in size of the tumor mass, lasting for at least twelve weeks.””
Why should anyone care about your comment re “STABLE DISEASE,” when the FDA has advised:
5/2007 – “Guidance for Industry – Food and Drug Administration”
“Clinical Trial Endpoints for the Approval of Cancer Drugs and Biologics”
“”STABLE DISEASE should not be a component of ORR”
“STABLE DISEASE can reflect the natural history of disease””
(Pg. 10 of 22 = actual pg. 7 of PDF)
“…STABLE DISEASE can be more accurately assessed by TTP or PFS analysis (see below)”
“Also, STABLE DISEASE can be more accurately assessed by TTP or PFS analysis (see below)”
(Pg. 11 of 22 = actual pg. 8 of PDF)
“Time to Progression and Progression-Free Survival”
“TTP – Time to Progression”
“PFS – Progression-Free Survival”
“TTP and PFS have served as primary endpoints for drug approval”
(Pg. 11 of 22 = actual pg. 8 of PDF)
http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm071590.pdf
And in addition, the below 2005 non-Burzynski study also uses “STABLE DISEASE?”
Role of temozolomide after radiotherapy for newly diagnosed diffuse brainstem glioma in children
Results of a multiinstitutional study (SJHG-98)
http://www.ncbi.nlm.nih.gov/m/pubmed/15565574
Peter Lipson: “Speech is best countered by more speech”
Reply

Didymus Thomas 2 hours ago
Mr. Chapman, where does the Declaration of Helsinki indicate WHEN human clinical trials results MUST be published?
I do NOT see it listed on the National Institutes of Health, Helsinki document:
http://history.nih.gov/research/downloads/helsinki.pdf
Peter Lipson: “Speech is best countered by more speech”
Reply

Didymus Thomas 2 hours ago
Mr. Morgan, is this the Kurume Japanese case study you are referring to?
RANDOMIZED PHASE II STUDY of Hepatic Arterial Infusion with or without ANTINEOPLASTONS as Adjuvant Therapy after Hepatectomy for liver Metastases from Colorectal Cancer
http://www.colorectal-cancer.ca/IMG/pdf/CCAC_Research_June_19_2009.pdf
Annals of Oncology 2010;21:viii221
Game Over?
Peter Lipson: “Speech is best countered by more speech”
Reply

Didymus Thomas 1 hour ago
Mr. Ogon, you commented:
“You are right now having a live “debate” in front of more than 10,000 people … ”
I checked the “
views” of this article and it was only 2,420 views
Please advise when the “live “debate” in front of more than 10,000 people,” will occur
Peter Lipson: “Speech is best countered by more speech”
Reply

Didymus Thomas 1 minute ago
Mr. Ogon, you made various comments re clinical trials, impact factors, etc.
Why should anyone care about your comments when the “National Cancer Institute (NCI) at the National Institutes of Health (NIH), Cancer Clinical Trials, 15. What happens when a clinical trial is over?,” advises:
“The results of clinical trials are OFTEN published in peer-reviewed scientific journals”
” … WHETHER OR NOT the results are published in a peer-reviewed scientific journal … ”
This makes it clear that clinical trial results “
are OFTEN” published, but sometimes they are “NOT” published “in a peer-reviewed scientific journal”
Peter Lipson: “Speech is best countered by more speech”
Reply

Thank you for submitting your comment:

New comments typically appear within 30 seconds.

Mr. Chapman, you commented:
” … the failure to publish any usable results from any single trial is grossly unethical”
“The FDA’s Drug Review Process: Ensuring Drugs Are Safe and Effective” advises:
“[T]he emphasis in Phase 2 is on EFFECTIVENESS”
“This phase aims to obtain PRELIMINARY DATA on whether the drug works in people who have a certain disease or condition”
“Phase 3 studies begin if EVIDENCE of EFFECTIVENESS is shown in Phase 2″
“These studies gather more information about safety and EFFECTIVENESS, studying different populations and different dosages and using the drug in combination with other drugs”
I have already previously addressed the issue of publication re comments made by Mr. Ogon, before you made your most recent comment concerning the same subject.
Please see my reply to him.

Once you have done that, please advise how your ” … the failure to publish any usable results from any single trial is grossly unethical,” comment is relevant.
What is the relevance of publishing results of phase 2 clinical trials if it is only “PRELIMINARY DATA,” and NOT waiting until phase 3 study which would “gather more information about safety and EFFECTIVENESS”?

Share your comment:
facebook
linkedin
twitter

Mr. Ogon, you commented:
“One further has to take into account the fact that Scamley has been known to employ idiosyncratic definitions, such as classifying tumor *growth* as “STABLE DISEASE” for “less than 50% reduction in size but no more than 50% increase in size of the tumor mass, lasting for at least twelve weeks.””
Why should anyone care about your comment re “STABLE DISEASE,” when the FDA has advised:
5/2007 – “Guidance for Industry – Food and Drug Administration”
“Clinical Trial Endpoints for the Approval of Cancer Drugs and Biologics”
“”STABLE DISEASE should not be a component of ORR”
“STABLE DISEASE can reflect the natural history of disease””
(Pg. 10 of 22 = actual pg. 7 of PDF)
“…STABLE DISEASE can be more accurately assessed by TTP or PFS analysis (see below)”
“Also, STABLE DISEASE can be more accurately assessed by TTP or PFS analysis (see below)”
(Pg. 11 of 22 = actual pg. 8 of PDF)
“Time to Progression and Progression-Free Survival”
“TTP – Time to Progression”
“PFS – Progression-Free Survival”
“TTP and PFS have served as primary endpoints for drug approval”
(Pg. 11 of 22 = actual pg. 8 of PDF)
http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm071590.pdf
And in addition, the below 2005 non-Burzynski study also uses “STABLE DISEASE?”
Role of temozolomide after radiotherapy for newly diagnosed diffuse brainstem glioma in children
Results of a multiinstitutional study (SJHG-98)
http://www.ncbi.nlm.nih.gov/m/pubmed/15565574
Peter Lipson: “Speech is best countered by more speech”
Reply

Didymus Thomas 2 hours ago
Mr. Chapman, where does the Declaration of Helsinki indicate WHEN human clinical trials results MUST be published?
I do NOT see it listed on the National Institutes of Health, Helsinki document:
http://history.nih.gov/research/downloads/helsinki.pdf
Peter Lipson: “Speech is best countered by more speech”
Reply

Didymus Thomas 2 hours ago
Mr. Morgan, is this the Kurume Japanese case study you are referring to?
RANDOMIZED PHASE II STUDY of Hepatic Arterial Infusion with or without ANTINEOPLASTONS as Adjuvant Therapy after Hepatectomy for liver Metastases from Colorectal Cancer
http://www.colorectal-cancer.ca/IMG/pdf/CCAC_Research_June_19_2009.pdf
Annals of Oncology 2010;21:viii221
Game Over?
Peter Lipson: “Speech is best countered by more speech”
Reply

Didymus Thomas 1 hour ago
Mr. Ogon, you commented:
“You are right now having a live “debate” in front of more than 10,000 people … ”
I checked the “
views” of this article and it was only 2,420 views
Please advise when the “live “debate” in front of more than 10,000 people,” will occur
Peter Lipson: “Speech is best countered by more speech”
Reply

Didymus Thomas 13 minutes ago
Mr. Ogon, you made various comments re clinical trials, impact factors, etc.
Why should anyone care about your comments when the “National Cancer Institute (NCI) at the National Institutes of Health (NIH), Cancer Clinical Trials, 15. What happens when a clinical trial is over?,” advises:
“The results of clinical trials are OFTEN published in peer-reviewed scientific journals”
” … WHETHER OR NOT the results are published in a peer-reviewed scientific journal … ”
This makes it clear that clinical trial results “
are OFTEN” published, but sometimes they are “NOT” published “in a peer-reviewed scientific journal”
Peter Lipson: “Speech is best countered by more speech”
Reply

Didymus Thomas 1 minute ago
Mr. Chapman, you commented:
” … the failure to publish any usable results from any single trial is grossly unethical”
“ The FDA’s Drug Review Process: Ensuring Drugs Are Safe and Effective” advises:
“[T]he emphasis in Phase 2 is on EFFECTIVENESS”
“This phase aims to obtain PRELIMINARY DATA on whether the drug works in people who have a certain disease or condition”
“Phase 3 studies begin if EVIDENCE of EFFECTIVENESS is shown in Phase 2″
“These studies gather more information about safety and EFFECTIVENESS, studying different populations and different dosages and using the drug in combination with other drugs”
I have already previously addressed the issue of publication re comments made by Mr. Ogon, before you made your most recent comment concerning the same subject.
Please see my reply to him.
Once you have done that, please advise how your ” … the failure to publish any usable results from any single trial is grossly unethical,” comment is relevant.
What is the relevance of publishing results of phase 2 clinical trials if it is only “ PRELIMINARY DATA,” and NOT waiting until phase 3 study which would “gather more information about safety and EFFECTIVENESS”?
Reply

Thank you for submitting your comment:

New comments typically appear within 30 seconds.

Mr. Morgan, your clinical trial data for Burzynski differs from what the National Cancer Institute (NCI) at the National Institutes of Health (NIH) has when you follow the links on ClinicalTrials . gov, which is supposedly sourced from the NCI:
61 TOTAL
1 – Not Yet Recruiting (Open)(Phase 3)
1 – Closed
2 – Terminated (Withdrawn due to slow enrollment)
7 – Withdrawn (This study has been withdrawn prior to enrollment)
10 – Recruiting (Open)
11 – Open (1 Not Yet Recruiting / 10 Recruiting)
40 – Active, not recruiting (Closed)
With the data being different between the 2 sources, how are we supposed to know what is correct?

Didymus Thomas 3 hours ago
Mr. Ogon, you commented:
“One further has to take into account the fact that Scamley has been known to employ idiosyncratic definitions, such as classifying tumor *growth* as “STABLE DISEASE” for “less than 50% reduction in size but no more than 50% increase in size of the tumor mass, lasting for at least twelve weeks.””
Why should anyone care about your comment re “STABLE DISEASE,” when the FDA has advised:
5/2007 – “Guidance for Industry – Food and Drug Administration”
“Clinical Trial Endpoints for the Approval of Cancer Drugs and Biologics”
“”STABLE DISEASE should not be a component of ORR”
“STABLE DISEASE can reflect the natural history of disease””
(Pg. 10 of 22 = actual pg. 7 of PDF)
“…STABLE DISEASE can be more accurately assessed by TTP or PFS analysis (see below)”
“Also, STABLE DISEASE can be more accurately assessed by TTP or PFS analysis (see below)”
(Pg. 11 of 22 = actual pg. 8 of PDF)
“Time to Progression and Progression-Free Survival”
“TTP – Time to Progression”
“PFS – Progression-Free Survival”
“TTP and PFS have served as primary endpoints for drug approval”
(Pg. 11 of 22 = actual pg. 8 of PDF)
http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm071590.pdf
And in addition, the below 2005 non-Burzynski study also uses “STABLE DISEASE?”
Role of temozolomide after radiotherapy for newly diagnosed diffuse brainstem glioma in children
Results of a multiinstitutional study (SJHG-98)
http://www.ncbi.nlm.nih.gov/m/pubmed/15565574
Peter Lipson: “Speech is best countered by more speech”
Reply

Didymus Thomas 2 hours ago
Mr. Chapman, where does the Declaration of Helsinki indicate WHEN human clinical trials results MUST be published?
I do NOT see it listed on the National Institutes of Health, Helsinki document:
http://history.nih.gov/research/downloads/helsinki.pdf
Peter Lipson: “Speech is best countered by more speech”
Reply

Didymus Thomas 2 hours ago
Mr. Morgan, is this the Kurume Japanese case study you are referring to?
RANDOMIZED PHASE II STUDY of Hepatic Arterial Infusion with or without ANTINEOPLASTONS as Adjuvant Therapy after Hepatectomy for liver Metastases from Colorectal Cancer
http://www.colorectal-cancer.ca/IMG/pdf/CCAC_Research_June_19_2009.pdf
Annals of Oncology 2010;21:viii221
Game Over?
Peter Lipson: “Speech is best countered by more speech”
Reply

Didymus Thomas 2 hours ago
Mr. Ogon, you commented:
“You are right now having a live “debate” in front of more than 10,000 people … ”
I checked the “
views” of this article and it was only 2,420 views
Please advise when the “live “debate” in front of more than 10,000 people,” will occur
Peter Lipson: “Speech is best countered by more speech”
Reply

Didymus Thomas 27 minutes ago
Mr. Ogon, you made various comments re clinical trials, impact factors, etc.
Why should anyone care about your comments when the “National Cancer Institute (NCI) at the National Institutes of Health (NIH), Cancer Clinical Trials, 15. What happens when a clinical trial is over?,” advises:
“The results of clinical trials are OFTEN published in peer-reviewed scientific journals”
” … WHETHER OR NOT the results are published in a peer-reviewed scientific journal … ”
This makes it clear that clinical trial results “
are OFTEN” published, but sometimes they are “NOT” published “in a peer-reviewed scientific journal”
Peter Lipson: “Speech is best countered by more speech”
Reply

Didymus Thomas 15 minutes ago
Mr. Chapman, you commented:
” … the failure to publish any usable results from any single trial is grossly unethical”
“ The FDA’s Drug Review Process: Ensuring Drugs Are Safe and Effective” advises:
“[T]he emphasis in Phase 2 is on EFFECTIVENESS”
“This phase aims to obtain PRELIMINARY DATA on whether the drug works in people who have a certain disease or condition”
“Phase 3 studies begin if EVIDENCE of EFFECTIVENESS is shown in Phase 2″
“These studies gather more information about safety and EFFECTIVENESS, studying different populations and different dosages and using the drug in combination with other drugs”
I have already previously addressed the issue of publication re comments made by Mr. Ogon, before you made your most recent comment concerning the same subject.
Please see my reply to him.
Once you have done that, please advise how your ” … the failure to publish any usable results from any single trial is grossly unethical,” comment is relevant.
What is the relevance of publishing results of phase 2 clinical trials if it is only “ PRELIMINARY DATA,” and NOT waiting until phase 3 study which would “gather more information about safety and EFFECTIVENESS”?
Reply

Didymus Thomas 2 minutes ago
Mr. Morgan, your clinical trial data for Burzynski differs from what the National Cancer Institute (NCI) at the National Institutes of Health (NIH) has when you follow the links on ClinicalTrials . gov, which is supposedly sourced from the NCI:
61 TOTAL
1 – Not Yet Recruiting (Open)(Phase 3)
1 – Closed
2 – Terminated (Withdrawn due to slow enrollment)
7 – Withdrawn (This study has been withdrawn prior to enrollment)
10 – Recruiting (Open)
11 – Open (1 Not Yet Recruiting / 10 Recruiting)
40 – Active, not recruiting (Closed)
With the data being different between the 2 sources, how are we supposed to know what is correct?
Peter Lipson: “Speech is best countered by more speech”

Thank you for submitting your comment:

New comments typically appear within 30 seconds.

Mr. Ogon, I’m not exactly who you were replying to, but you refer to a “25% cure rate,” and in the below 2 studies, neither one mentions a “25% cure rate” in it:
“You mean PMIDs” re Drugs R D. 2003;4(2):91-101 “and ” Integr Cancer Ther. 2006 Mar;5(1):40-7? “(These, at least, are the ones that Merola cites, which I assume is the sum total of your “fact checking.”)”
You then go on to comment:
“(2) it’s essentially the same group in both”
However, the dosages in the 2 studies are different, so I am not certain how you came to the above conclusion
Peter Lipson: “Speech is best countered by more speech”

Share your comment:
facebook
linkedin
twitter

Didymus Thomas 3 hours ago
Mr. Ogon, you commented:
“One further has to take into account the fact that Scamley has been known to employ idiosyncratic definitions, such as classifying tumor *growth* as “STABLE DISEASE” for “less than 50% reduction in size but no more than 50% increase in size of the tumor mass, lasting for at least twelve weeks.””
Why should anyone care about your comment re “STABLE DISEASE,” when the FDA has advised:
5/2007 – “Guidance for Industry – Food and Drug Administration”
“Clinical Trial Endpoints for the Approval of Cancer Drugs and Biologics”
“”STABLE DISEASE should not be a component of ORR”
“STABLE DISEASE can reflect the natural history of disease””
(Pg. 10 of 22 = actual pg. 7 of PDF)
“…STABLE DISEASE can be more accurately assessed by TTP or PFS analysis (see below)”
“Also, STABLE DISEASE can be more accurately assessed by TTP or PFS analysis (see below)”
(Pg. 11 of 22 = actual pg. 8 of PDF)
“Time to Progression and Progression-Free Survival”
“TTP – Time to Progression”
“PFS – Progression-Free Survival”
“TTP and PFS have served as primary endpoints for drug approval”
(Pg. 11 of 22 = actual pg. 8 of PDF)
http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm071590.pdf
And in addition, the below 2005 non-Burzynski study also uses “STABLE DISEASE?”
Role of temozolomide after radiotherapy for newly diagnosed diffuse brainstem glioma in children
Results of a multiinstitutional study (SJHG-98)
http://www.ncbi.nlm.nih.gov/m/pubmed/15565574
Peter Lipson: “Speech is best countered by more speech”

Didymus Thomas 3 hours ago
Mr. Chapman, where does the Declaration of Helsinki indicate WHEN human clinical trials results MUST be published?
I do NOT see it listed on the National Institutes of Health, Helsinki document:
http://history.nih.gov/research/downloads/helsinki.pdf
Peter Lipson: “Speech is best countered by more speech”

Didymus Thomas 2 hours ago
Mr. Morgan, is this the Kurume Japanese case study you are referring to?
RANDOMIZED PHASE II STUDY of Hepatic Arterial Infusion with or without ANTINEOPLASTONS as Adjuvant Therapy after Hepatectomy for liver Metastases from Colorectal Cancer
http://www.colorectal-cancer.ca/IMG/pdf/CCAC_Research_June_19_2009.pdf
Annals of Oncology 2010;21:viii221
Game Over?
Peter Lipson: “Speech is best countered by more speech”

Didymus Thomas 2 hours ago
Mr. Ogon, you commented:
“You are right now having a live “debate” in front of more than 10,000 people … ”
I checked the “
views” of this article and it was only 2,420 views
Please advise when the “live “debate” in front of more than 10,000 people,” will occur
Peter Lipson: “Speech is best countered by more speech”

Didymus Thomas 44 minutes ago
Mr. Ogon, you made various comments re clinical trials, impact factors, etc.
Why should anyone care about your comments when the “National Cancer Institute (NCI) at the National Institutes of Health (NIH), Cancer Clinical Trials, 15. What happens when a clinical trial is over?,” advises:
“The results of clinical trials are OFTEN published in peer-reviewed scientific journals”
” … WHETHER OR NOT the results are published in a peer-reviewed scientific journal … ”
This makes it clear that clinical trial results “
are OFTEN” published, but sometimes they are “NOT” published “in a peer-reviewed scientific journal”
Peter Lipson: “Speech is best countered by more speech”

Didymus Thomas 33 minutes ago
Mr. Chapman, you commented:
” … the failure to publish any usable results from any single trial is grossly unethical”
“ The FDA’s Drug Review Process: Ensuring Drugs Are Safe and Effective” advises:
“[T]he emphasis in Phase 2 is on EFFECTIVENESS”
“This phase aims to obtain PRELIMINARY DATA on whether the drug works in people who have a certain disease or condition”
“Phase 3 studies begin if EVIDENCE of EFFECTIVENESS is shown in Phase 2″
“These studies gather more information about safety and EFFECTIVENESS, studying different populations and different dosages and using the drug in combination with other drugs”
I have already previously addressed the issue of publication re comments made by Mr. Ogon, before you made your most recent comment concerning the same subject.
Please see my reply to him.
Once you have done that, please advise how your ” … the failure to publish any usable results from any single trial is grossly unethical,” comment is relevant.
What is the relevance of publishing results of phase 2 clinical trials if it is only “ PRELIMINARY DATA,” and NOT waiting until phase 3 study which would “gather more information about safety and EFFECTIVENESS”?

Didymus Thomas 19 minutes ago
Mr. Morgan, your clinical trial data for Burzynski differs from what the National Cancer Institute (NCI) at the National Institutes of Health (NIH) has when you follow the links on ClinicalTrials . gov, which is supposedly sourced from the NCI:
61 TOTAL
1 – Not Yet Recruiting (Open)(Phase 3)
1 – Closed
2 – Terminated (Withdrawn due to slow enrollment)
7 – Withdrawn (This study has been withdrawn prior to enrollment)
10 – Recruiting (Open)
11 – Open (1 Not Yet Recruiting / 10 Recruiting)
40 – Active, not recruiting (Closed)
With the data being different between the 2 sources, how are we supposed to know what is correct?
Peter Lipson: “Speech is best countered by more speech”

Didymus Thomas 3 minutes ago
Mr. Ogon, I’m not exactly who you were replying to, but you refer to a “25% cure rate,” and in the below 2 studies, neither one mentions a “25% cure rate” in it:
“You mean PMIDs” re Drugs R D. 2003;4(2):91-101 “and ” Integr Cancer Ther. 2006 Mar;5(1):40-7? “ (These, at least, are the ones that Merola cites, which I assume is the sum total of your “fact checking.”)”
You then go on to comment:
“(2) it’s essentially the same group in both”
However, the dosages in the 2 studies are different, so I am not certain how you came to the above conclusion
Peter Lipson: “Speech is best countered by more speech”

Mr. Ogon, why is “HYPERNATREMIA” and “SEIZURES” NOT listed on the National Cancer Institute (NCI) at the National Institutes of Health (NIH) list of ADVERSE EFFECTS for antineoplastons?
Peter Lipson: “Speech is best countered by more speech”

Share your comment:
facebook
linkedin
twitter

Thank you for submitting your comment:

New comments typically appear within 30 seconds.

Mr. Ogon, why is “HYPERNATREMIA” and “SEIZURES” NOT listed on the National Cancer Institute (NCI) at the National Institutes of Health (NIH) list of ADVERSE EFFECTS for antineoplastons?
Peter Lipson: “Speech is best countered by more speech”

Share your comment:
facebook
linkedin
twitter

Didymus Thomas 4 hours ago
Mr. Ogon, you commented:
“One further has to take into account the fact that Scamley has been known to employ idiosyncratic definitions, such as classifying tumor *growth* as “STABLE DISEASE” for “less than 50% reduction in size but no more than 50% increase in size of the tumor mass, lasting for at least twelve weeks.””
Why should anyone care about your comment re “STABLE DISEASE,” when the FDA has advised:
5/2007 – “Guidance for Industry – Food and Drug Administration”
“Clinical Trial Endpoints for the Approval of Cancer Drugs and Biologics”
“”STABLE DISEASE should not be a component of ORR”
“STABLE DISEASE can reflect the natural history of disease””
(Pg. 10 of 22 = actual pg. 7 of PDF)
“…STABLE DISEASE can be more accurately assessed by TTP or PFS analysis (see below)”
“Also, STABLE DISEASE can be more accurately assessed by TTP or PFS analysis (see below)”
(Pg. 11 of 22 = actual pg. 8 of PDF)
“Time to Progression and Progression-Free Survival”
“TTP – Time to Progression”
“PFS – Progression-Free Survival”
“TTP and PFS have served as primary endpoints for drug approval”
(Pg. 11 of 22 = actual pg. 8 of PDF)
http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm071590.pdf
And in addition, the below 2005 non-Burzynski study also uses “STABLE DISEASE?”
Role of temozolomide after radiotherapy for newly diagnosed diffuse brainstem glioma in children
Results of a multiinstitutional study (SJHG-98)
http://www.ncbi.nlm.nih.gov/m/pubmed/15565574
Peter Lipson: “Speech is best countered by more speech”
Reply

Didymus Thomas 3 hours ago
Mr. Chapman, where does the Declaration of Helsinki indicate WHEN human clinical trials results MUST be published?
I do NOT see it listed on the National Institutes of Health, Helsinki document:
http://history.nih.gov/research/downloads/helsinki.pdf
Peter Lipson: “Speech is best countered by more speech”
Reply

Didymus Thomas 3 hours ago
Mr. Morgan, is this the Kurume Japanese case study you are referring to?
RANDOMIZED PHASE II STUDY of Hepatic Arterial Infusion with or without ANTINEOPLASTONS as Adjuvant Therapy after Hepatectomy for liver Metastases from Colorectal Cancer
http://www.colorectal-cancer.ca/IMG/pdf/CCAC_Research_June_19_2009.pdf
Annals of Oncology 2010;21:viii221
Game Over?
Peter Lipson: “Speech is best countered by more speech”
Reply

Didymus Thomas 2 hours ago
Mr. Ogon, you commented:
“You are right now having a live “debate” in front of more than 10,000 people … ”
I checked the “
views” of this article and it was only 2,420 views
Please advise when the “live “debate” in front of more than 10,000 people,” will occur
Peter Lipson: “Speech is best countered by more speech”
Reply

Didymus Thomas 1 hour ago
Mr. Ogon, you made various comments re clinical trials, impact factors, etc.
Why should anyone care about your comments when the “National Cancer Institute (NCI) at the National Institutes of Health (NIH), Cancer Clinical Trials, 15. What happens when a clinical trial is over?,” advises:
“The results of clinical trials are OFTEN published in peer-reviewed scientific journals”
” … WHETHER OR NOT the results are published in a peer-reviewed scientific journal … ”
This makes it clear that clinical trial results “
are OFTEN” published, but sometimes they are “NOT” published “in a peer-reviewed scientific journal”
Peter Lipson: “Speech is best countered by more speech”
Reply

Didymus Thomas 1 hour ago
Mr. Chapman, you commented:
” … the failure to publish any usable results from any single trial is grossly unethical”
“ The FDA’s Drug Review Process: Ensuring Drugs Are Safe and Effective” advises:
“[T]he emphasis in Phase 2 is on EFFECTIVENESS”
“This phase aims to obtain PRELIMINARY DATA on whether the drug works in people who have a certain disease or condition”
“Phase 3 studies begin if EVIDENCE of EFFECTIVENESS is shown in Phase 2″
“These studies gather more information about safety and EFFECTIVENESS, studying different populations and different dosages and using the drug in combination with other drugs”
I have already previously addressed the issue of publication re comments made by Mr. Ogon, before you made your most recent comment concerning the same subject.
Please see my reply to him.
Once you have done that, please advise how your ” … the failure to publish any usable results from any single trial is grossly unethical,” comment is relevant.
What is the relevance of publishing results of phase 2 clinical trials if it is only “ PRELIMINARY DATA,” and NOT waiting until phase 3 study which would “gather more information about safety and EFFECTIVENESS”?
Reply

Didymus Thomas 49 minutes ago
Mr. Morgan, your clinical trial data for Burzynski differs from what the National Cancer Institute (NCI) at the National Institutes of Health (NIH) has when you follow the links on ClinicalTrials . gov, which is supposedly sourced from the NCI:
61 TOTAL
1 – Not Yet Recruiting (Open)(Phase 3)
1 – Closed
2 – Terminated (Withdrawn due to slow enrollment)
7 – Withdrawn (This study has been withdrawn prior to enrollment)
10 – Recruiting (Open)
11 – Open (1 Not Yet Recruiting / 10 Recruiting)
40 – Active, not recruiting (Closed)
With the data being different between the 2 sources, how are we supposed to know what is correct?
Peter Lipson: “Speech is best countered by more speech”
Reply

Didymus Thomas 33 minutes ago
Mr. Ogon, I’m not exactly who you were replying to, but you refer to a “25% cure rate,” and in the below 2 studies, neither one mentions a “25% cure rate” in it:
“You mean PMIDs” re Drugs R D. 2003;4(2):91-101 “and ” Integr Cancer Ther. 2006 Mar;5(1):40-7? “ (These, at least, are the ones that Merola cites, which I assume is the sum total of your “fact checking.”)”
You then go on to comment:
“(2) it’s essentially the same group in both”
However, the dosages in the 2 studies are different, so I am not certain how you came to the above conclusion
Peter Lipson: “Speech is best countered by more speech”
Reply

Didymus Thomas 3 minutes ago
Mr. Ogon, why is “HYPERNATREMIA” and “SEIZURES” NOT listed on the National Cancer Institute (NCI) at the National Institutes of Health (NIH) list of ADVERSE EFFECTS for
Peter Lipson: “Speech is best countered by more speech”

Thank you for submitting your comment:

New comments typically appear within 30 seconds.

FW, you commented re Burzynski’s Phase 3 clinical trial:
“Unfortunately it backfired, because he seems quite happy to never start this trial, instead using it as a marketing tool, in the same way as he is happy to use individual patients”
Burzynski’s Securities and Exchange Commission (SEC) Form 10-Q for the quarterly period ended 5/31/2010 states:
1/13/2009 Company announced Company had reached an agreement with FDA for Company to move forward with pivotal Phase III clinical trial of combination Antineoplaston therapy plus radiation therapy in patients with newly diagnosed, diffuse, intrinsic brainstem gliomas (DBSG)
Agreement was made under FDA’s Special Protocol Assessment procedure, meaning design and planned analysis of Phase III study is acceptable to support regulatory submission seeking new drug approval
2/1/2010 Company entered into agreement with Cycle Solutions, Inc., dba ResearchPoint to initiate and manage pivotal Phase III clinical trial of combination Antineoplastons A10 and AS2-1 plus radiation therapy (RT) in patients with newly-diagnosed, diffuse, intrinsic brainstem glioma
ResearchPoint is currently conducting feasibility assessment
ResearchPoint has secured interest and commitment from number of sites selected
Upon completion of assessment, randomized, international phase III study will commence
Study’s objective is to compare overall survival of children with newly-diagnosed DBSG who receive combination Antineoplastons A10 and AS2-1 plus RT versus RT alone
Peter Lipson: “Speech is best countered by more speech”

Share your comment:
facebook
linkedin
twitter

Didymus Thomas 4 hours ago
Mr. Ogon, you commented:
“One further has to take into account the fact that Scamley has been known to employ idiosyncratic definitions, such as classifying tumor *growth* as “STABLE DISEASE” for “less than 50% reduction in size but no more than 50% increase in size of the tumor mass, lasting for at least twelve weeks.””
Why should anyone care about your comment re “STABLE DISEASE,” when the FDA has advised:
5/2007 – “Guidance for Industry – Food and Drug Administration”
“Clinical Trial Endpoints for the Approval of Cancer Drugs and Biologics”
“”STABLE DISEASE should not be a component of ORR”
“STABLE DISEASE can reflect the natural history of disease””
(Pg. 10 of 22 = actual pg. 7 of PDF)
“…STABLE DISEASE can be more accurately assessed by TTP or PFS analysis (see below)”
“Also, STABLE DISEASE can be more accurately assessed by TTP or PFS analysis (see below)”
(Pg. 11 of 22 = actual pg. 8 of PDF)
“Time to Progression and Progression-Free Survival”
“TTP – Time to Progression”
“PFS – Progression-Free Survival”
“TTP and PFS have served as primary endpoints for drug approval”
(Pg. 11 of 22 = actual pg. 8 of PDF)
http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm071590.pdf
And in addition, the below 2005 non-Burzynski study also uses “STABLE DISEASE?”
Role of temozolomide after radiotherapy for newly diagnosed diffuse brainstem glioma in children
Results of a multiinstitutional study (SJHG-98)
http://www.ncbi.nlm.nih.gov/m/pubmed/15565574
Peter Lipson: “Speech is best countered by more speech”
Reply

Didymus Thomas 4 hours ago
Mr. Chapman, where does the Declaration of Helsinki indicate WHEN human clinical trials results MUST be published?
I do NOT see it listed on the National Institutes of Health, Helsinki document:
http://history.nih.gov/research/downloads/helsinki.pdf
Peter Lipson: “Speech is best countered by more speech”
Reply

Didymus Thomas 4 hours ago
Mr. Morgan, is this the Kurume Japanese case study you are referring to?
RANDOMIZED PHASE II STUDY of Hepatic Arterial Infusion with or without ANTINEOPLASTONS as Adjuvant Therapy after Hepatectomy for liver Metastases from Colorectal Cancer
http://www.colorectal-cancer.ca/IMG/pdf/CCAC_Research_June_19_2009.pdf
Annals of Oncology 2010;21:viii221
Game Over?
Peter Lipson: “Speech is best countered by more speech”
Reply

Didymus Thomas 3 hours ago
Mr. Ogon, you commented:
“You are right now having a live “debate” in front of more than 10,000 people … ”
I checked the “
views” of this article and it was only 2,420 views
Please advise when the “live “debate” in front of more than 10,000 people,” will occur
Peter Lipson: “Speech is best countered by more speech”
Reply

Didymus Thomas 1 hour ago
Mr. Ogon, you made various comments re clinical trials, impact factors, etc.
Why should anyone care about your comments when the “National Cancer Institute (NCI) at the National Institutes of Health (NIH), Cancer Clinical Trials, 15. What happens when a clinical trial is over?,” advises:
“The results of clinical trials are OFTEN published in peer-reviewed scientific journals”
” … WHETHER OR NOT the results are published in a peer-reviewed scientific journal … ”
This makes it clear that clinical trial results “
are OFTEN” published, but sometimes they are “NOT” published “in a peer-reviewed scientific journal”
Peter Lipson: “Speech is best countered by more speech”
Reply

Didymus Thomas 1 hour ago
Mr. Chapman, you commented:
” … the failure to publish any usable results from any single trial is grossly unethical”
“ The FDA’s Drug Review Process: Ensuring Drugs Are Safe and Effective” advises:
“[T]he emphasis in Phase 2 is on EFFECTIVENESS”
“This phase aims to obtain PRELIMINARY DATA on whether the drug works in people who have a certain disease or condition”
“Phase 3 studies begin if EVIDENCE of EFFECTIVENESS is shown in Phase 2″
“These studies gather more information about safety and EFFECTIVENESS, studying different populations and different dosages and using the drug in combination with other drugs”
I have already previously addressed the issue of publication re comments made by Mr. Ogon, before you made your most recent comment concerning the same subject.
Please see my reply to him.
Once you have done that, please advise how your ” … the failure to publish any usable results from any single trial is grossly unethical,” comment is relevant.
What is the relevance of publishing results of phase 2 clinical trials if it is only “ PRELIMINARY DATA,” and NOT waiting until phase 3 study which would “gather more information about safety and EFFECTIVENESS”?
Reply

Didymus Thomas 1 hour ago
Mr. Morgan, your clinical trial data for Burzynski differs from what the National Cancer Institute (NCI) at the National Institutes of Health (NIH) has when you follow the links on ClinicalTrials . gov, which is supposedly sourced from the NCI:
61 TOTAL
1 – Not Yet Recruiting (Open)(Phase 3)
1 – Closed
2 – Terminated (Withdrawn due to slow enrollment)
7 – Withdrawn (This study has been withdrawn prior to enrollment)
10 – Recruiting (Open)
11 – Open (1 Not Yet Recruiting / 10 Recruiting)
40 – Active, not recruiting (Closed)
With the data being different between the 2 sources, how are we supposed to know what is correct?
Peter Lipson: “Speech is best countered by more speech”
Reply

Didymus Thomas 1 hour ago
Mr. Ogon, I’m not exactly who you were replying to, but you refer to a “25% cure rate,” and in the below 2 studies, neither one mentions a “25% cure rate” in it:
“You mean PMIDs” re Drugs R D. 2003;4(2):91-101 “and ” Integr Cancer Ther. 2006 Mar;5(1):40-7? “ (These, at least, are the ones that Merola cites, which I assume is the sum total of your “fact checking.”)”
You then go on to comment:
“(2) it’s essentially the same group in both”
However, the dosages in the 2 studies are different, so I am not certain how you came to the above conclusion
Peter Lipson: “Speech is best countered by more speech”
Reply

Didymus Thomas 43 minutes ago
Mr. Ogon, why is “HYPERNATREMIA” and “SEIZURES” NOT listed on the National Cancer Institute (NCI) at the National Institutes of Health (NIH) list of ADVERSE EFFECTS for antineoplastons?
Peter Lipson: “Speech is best countered by more speech”
Reply

Didymus Thomas 8 minutes ago
FW, you commented re Burzynski’s Phase 3 clinical trial:
“Unfortunately it backfired, because he seems quite happy to never start this trial, instead using it as a marketing tool, in the same way as he is happy to use individual patients”
Burzynski’s Securities and Exchange Commission (SEC) Form 10-Q for the quarterly period ended 5/31/2010 states:
1/13/2009 Company announced Company had reached an agreement with FDA for Company to move forward with pivotal Phase III clinical trial of combination Antineoplaston therapy plus radiation therapy in patients with newly diagnosed, diffuse, intrinsic brainstem gliomas (DBSG)
Agreement was made under FDA’s Special Protocol Assessment procedure, meaning design and planned analysis of Phase III study is acceptable to support regulatory submission seeking new drug approval
2/1/2010 Company entered into agreement with Cycle Solutions, Inc., dba ResearchPoint to initiate and manage pivotal Phase III clinical trial of combination Antineoplastons A10 and AS2-1 plus radiation therapy (RT) in patients with newly-diagnosed, diffuse, intrinsic brainstem glioma
ResearchPoint is currently conducting feasibility assessment
ResearchPoint has secured interest and commitment from number of sites selected
Upon completion of assessment, randomized, international phase III study will commence
Study’s objective is to compare overall survival of children with newly-diagnosed DBSG who receive combination Antineoplastons A10 and AS2-1 plus RT versus RT alone
Peter Lipson: “Speech is best countered by more speech”
Reply

Thank you for submitting your comment:

New comments typically appear within 30 seconds.

Mr. Ogon, you missed these 2 Burzynski 2004 and 2005 phase 2 clinical trial publications:
Phase II study of antineoplaston A10 and AS2-1 in children with recurrent and progressive multicentric glioma : a preliminary report
Drugs R D. 2004;5(6):315-26
Long-term survival of high-risk pediatric patients with primitive neuroectodermal tumors treated with antineoplastons A10 and AS2-1
Integr Cancer Ther. 2005 Jun;4(2):168-77
Peter Lipson: “Speech is best countered by more speech”

Share your comment:
facebook
linkedin
twitter

Didymus Thomas 4 minutes ago
Mr. Ogon, you missed these 2 Burzynski 2004 and 2005 phase 2 clinical trial publications:
Phase II study of antineoplaston A10 and AS2-1 in children with recurrent and progressive multicentric glioma : a preliminary report
Drugs R D. 2004;5(6):315-26
Long-term survival of high-risk pediatric patients with primitive neuroectodermal tumors treated with antineoplastons A10 and AS2-1
Integr Cancer Ther. 2005 Jun;4(2):168-77
Peter Lipson: “Speech is best countered by more speech”
Reply

Thank you for submitting your comment:

New comments typically appear within 30 seconds.

FW, you commented:
The FDA was ordered by a scientifically illiterate judge to allow these trials, they had no choice”
Where is the reference, citation, or link for this remarkable claim?
Peter Lipson: “Speech is best countered by more speech”

Share your comment:

Didymus Thomas 11 minutes ago
Mr. Ogon, you missed these 2 Burzynski 2004 and 2005 phase 2 clinical trial publications:
Phase II study of antineoplaston A10 and AS2-1 in children with recurrent and progressive multicentric glioma : a preliminary report
Drugs R D. 2004;5(6):315-26
Long-term survival of high-risk pediatric patients with primitive neuroectodermal tumors treated with antineoplastons A10 and AS2-1
Integr Cancer Ther. 2005 Jun;4(2):168-77
Peter Lipson: “Speech is best countered by more speech”
Reply

Didymus Thomas 1 minute ago
FW, you commented:
The FDA was ordered by a scientifically illiterate judge to allow these trials, they had no choice”
Where is the reference, citation, or link for this remarkable claim?
Peter Lipson: “Speech is best countered by more speech”
Reply

Thank you for submitting your comment:

New comments typically appear within 30 seconds.

Mr. Ogon, you commented:
“I take it that by “not harmful” you mean “aside from the possibly life-threatening HYPERNATREMIA …”
Did you know these FACTS re HYPERNATREMIA?
The frequency, cost, and clinical outcomes of HYPERNATREMIA in patients hospitalized to a comprehensive CANCER center
Over 3 month period in 2006 re 3,446 patients, most of the HYPERNATREMIA (90 %) was acquired during hospital stay
Support Care Cancer. 2013 Feb 13
DOI
10.1007/s00520-013-1734-6
HYPERNATREMIA in the U.S.:
“HYPERNATREMIA is the most common electrolyte disorder in the United States”
“In some cases, cancer may cause the condition …”
http://www.nlm.nih.gov/medlineplus/ency/article/000394.htm
Peter Lipson: “Speech is best countered by more speech”

Share your comment:
facebook
linkedin
twitter

4/19/2013 @ 9:43PM |2,516 views
A Film Producer, A Cancer Doctor, And Their Critics
106 comments, 4 called-out
Comment Now

Didymus Thomas 34 minutes ago
Mr. Ogon, you missed these 2 Burzynski 2004 and 2005 phase 2 clinical trial publications:
Phase II study of antineoplaston A10 and AS2-1 in children with recurrent and progressive multicentric glioma : a preliminary report
Drugs R D. 2004;5(6):315-26
Long-term survival of high-risk pediatric patients with primitive neuroectodermal tumors treated with antineoplastons A10 and AS2-1
Integr Cancer Ther. 2005 Jun;4(2):168-77
Peter Lipson: “Speech is best countered by more speech”
Reply

Didymus Thomas 25 minutes ago
FW, you commented:
The FDA was ordered by a scientifically illiterate judge to allow these trials, they had no choice”
Where is the reference, citation, or link for this remarkable claim?
Peter Lipson: “Speech is best countered by more speech”
Reply

Didymus Thomas 2 minutes ago
Mr. Ogon, you commented:
“I take it that by “not harmful” you mean “aside from the possibly life-threatening HYPERNATREMIA …”
Did you know these FACTS re HYPERNATREMIA?
The frequency, cost, and clinical outcomes of HYPERNATREMIA in patients hospitalized to a comprehensive CANCER center
Over 3 month period in 2006 re 3,446 patients, most of the HYPERNATREMIA (90 %) was acquired during hospital stay
Support Care Cancer. 2013 Feb 13
DOI
10.1007/s00520-013-1734-6
HYPERNATREMIA in the U.S.:
“HYPERNATREMIA is the most common electrolyte disorder in the United States”
“In some cases, cancer may cause the condition …”
http://www.nlm.nih.gov/medlineplus/ency/article/000394.htm
Peter Lipson: “Speech is best countered by more speech”
Reply

Thank you for submitting your comment:

New comments typically appear within 30 seconds.

Please note that the above study took place in 2006 and the results were just published in 2013
That’s around 7 to 8 years from the study end to when it was finally published
Peter Lipson: “Speech is best countered by more speech”

Share your comment:
facebook
linkedin
twitter

Didymus Thomas 49 minutes ago
Mr. Ogon, you missed these 2 Burzynski 2004 and 2005 phase 2 clinical trial publications:
Phase II study of antineoplaston A10 and AS2-1 in children with recurrent and progressive multicentric glioma : a preliminary report
Drugs R D. 2004;5(6):315-26
Long-term survival of high-risk pediatric patients with primitive neuroectodermal tumors treated with antineoplastons A10 and AS2-1
Integr Cancer Ther. 2005 Jun;4(2):168-77
Peter Lipson: “Speech is best countered by more speech”
Reply

Didymus Thomas 40 minutes ago
FW, you commented:
The FDA was ordered by a scientifically illiterate judge to allow these trials, they had no choice”
Where is the reference, citation, or link for this remarkable claim?
Peter Lipson: “Speech is best countered by more speech”
Reply

Didymus Thomas 17 minutes ago
Mr. Ogon, you commented:
“I take it that by “not harmful” you mean “aside from the possibly life-threatening HYPERNATREMIA …”
Did you know these FACTS re HYPERNATREMIA?
The frequency, cost, and clinical outcomes of HYPERNATREMIA in patients hospitalized to a comprehensive CANCER center
Over 3 month period in 2006 re 3,446 patients, most of the HYPERNATREMIA (90 %) was acquired during hospital stay
Support Care Cancer. 2013 Feb 13
DOI
10.1007/s00520-013-1734-6
HYPERNATREMIA in the U.S.:
“HYPERNATREMIA is the most common electrolyte disorder in the United States”
“In some cases, cancer may cause the condition …”
http://www.nlm.nih.gov/medlineplus/ency/article/000394.htm
Peter Lipson: “Speech is best countered by more speech”
Reply

Didymus Thomas 2 minutes ago
Please note that the above study took place in 2006 and the results were just published in 2013
That’s around 7 to 8 years from the study end to when it was finally published
Peter Lipson: “Speech is best countered by more speech”

TheSkeptiCritic (@TheSkeptiCritic) tweeted at 3:43pm – 22 Apr 13:
http://t.co/vh3cgAR6hW
“@SceptiGuy: Relevant to #Burzynski ”
Posts►Peter Lipson #Forbes
17►Guy•How many you have to repost?
14►Me•Numerous!!

forbes.com/sites/peterlip…—
(@TheSkeptiCritic) April 22, 2013

Thank you for submitting your comment:

New comments typically appear within 30 seconds.

Mr. Chapman, isn’t it problem that a number of the entities you list were engaged in this well documented “conspiracy”?
http://burzynskimovie.com/images/stories/transcript/Documents/BurzynskiTriesToExposeNCI.pdf
Peter Lipson: “Speech is best countered by more speech

Share your comment:
facebook
linkedin
twitter

TheSkeptiCritic (@TheSkeptiCritic) tweeted at 5:57pm – 22 Apr 13:
http://t.co/8PjEPukjpP…

https://twitter.com/TheSkeptiCritic/status/326469754116247552

guychapman 2 hours ago

Reply

Didymus Thomas 2 minutes ago
Mr. Chapman, isn’t it problem that a number of the entities you list were engaged in this well documented “conspiracy”?
http://burzynskimovie.com/images/stories/transcript/Documents/BurzynskiTriesToExposeNCI.pdf
Peter Lipson: “Speech is best countered by more speech
Reply

Thank you for submitting your comment:

New comments typically appear within 30 seconds.

Burzynski provided Clinical Trial data in the Form 10-Q Securities and Exchange Commission (SEC) filing For the fiscal year ended February 29, 2012
Peter Lipson: “Speech is best countered by more speech

Share your comment:
facebook
linkedin
twitter

guychapman 3 hours ago

Reply

Didymus Thomas 1 hour ago
Mr. Chapman, isn’t it problem that a number of the entities you list were engaged in this well documented “conspiracy”?
http://burzynskimovie.com/images/stories/transcript/Documents/BurzynskiTriesToExposeNCI.pdf
Peter Lipson: “Speech is best countered by more speech
Reply

Didymus Thomas 2 minutes ago
Burzynski provided Clinical Trial data in the Form 10-Q Securities and Exchange Commission (SEC) filing For the fiscal year ended February 29, 2012
Peter Lipson: “Speech is best countered by more speech
Reply

Thank you for submitting your comment:

guychapman 7 hours ago

Reply

Didymus Thomas 4 hours ago
Mr. Chapman, isn’t it problem that a number of the entities you list were engaged in this well documented “conspiracy”?
http://burzynskimovie.com/images/stories/transcript/Documents/BurzynskiTriesToExposeNCI.pdf
Peter Lipson: “Speech is best countered by more speech
Reply

Didymus Thomas 3 hours ago
Burzynski provided Clinical Trial data in the Form 10-Q Securities and Exchange Commission (SEC) filing For the fiscal year ended February 29, 2012
Peter Lipson: “Speech is best countered by more speech
Reply

Didymus Thomas 8 minutes ago
Enter Your CommentMr. Chapman, you employ a favorite tactic of critics like you.
It seems you are more interested in addressing form (CAPITALIZATION) over substance (the real issues).
Maybe you think that your verbosity (17 posts) will somehow lend credibility to your 3 comments re the Declaration of Helsinki; which does NOT state WHEN human clinical trial results MUST be published, and even though you have repeatedly proclaimed that Burzynski has NOT published the FINAL results of any of his phase 2 clinical trials, you have NOT provided any indication as to WHEN any of those trials were completed so that they can be compared to the 2006 study I cited whose results were published in 2013.
You also commented:
“In order to claim that he can cure incurable tumours, he needs to publish high quality clinical trial evidence in peer-reviewed journals,” yet you do NOT provide any citation, reference, or link that overrides the National Cancer Institute (NCI) at the National Institutes of Health (NIH) information re publication which I have commented on previously.
It is apropo you commented:
“Watergate only involved a handful of people and it was busted almost immediately,” since President Nixon is credited with starting the “War on Cancer,” and when Watergate occurred he was told that there was a cancer on the Presidency” but Watergate occurred in 1972 and Nixon didn’t resign until 2 years later, in 1974.
It is also appropriate that you mention oncologist David Gorski; who disclosed on social media that Peter Lipson is his “pal”
Did you review Burzynski’s 2003-2006 phase 2 clinical trials preliminary reports to see if any of the authors listed on them is an oncologist? No? That’s why your observation that Burzynski (a biochemist) is NOT an oncologist, is irrelevant.
Do you have any proof to back up your remarkable claim:
“Against that we have an anonymous shill who takes every word of the Burzynski clinic and its supporters as Revealed Truth”?
No? That’s because you’re wrong about that just like the other issues I’ve listed above.
Mr. Chapman, you attempts at obfuscation of the issues, does not impress.
Peter Lipson: “Speech is best countered by more speech”

New comments typically appear within 30 seconds.

Enter Your CommentMr. Chapman, you employ a favorite tactic of critics like you.
It seems you are more interested in addressing form (CAPITALIZATION) over substance (the real issues).
Maybe you think that your verbosity (17 posts) will somehow lend credibility to your 3 comments re the Declaration of Helsinki; which does NOT state WHEN human clinical trial results MUST be published, and even though you have repeatedly proclaimed that Burzynski has NOT published the FINAL results of any of his phase 2 clinical trials, you have NOT provided any indication as to WHEN any of those trials were completed so that they can be compared to the 2006 study I cited whose results were published in 2013.
You also commented:
“In order to claim that he can cure incurable tumours, he needs to publish high quality clinical trial evidence in peer-reviewed journals,” yet you do NOT provide any citation, reference, or link that overrides the National Cancer Institute (NCI) at the National Institutes of Health (NIH) information re publication which I have commented on previously.
It is apropo you commented:
“Watergate only involved a handful of people and it was busted almost immediately,” since President Nixon is credited with starting the “War on Cancer,” and when Watergate occurred he was told that there was a cancer on the Presidency” but Watergate occurred in 1972 and Nixon didn’t resign until 2 years later, in 1974.
It is also appropriate that you mention oncologist David Gorski; who disclosed on social media that Peter Lipson is his “pal”
Did you review Burzynski’s 2003-2006 phase 2 clinical trials preliminary reports to see if any of the authors listed on them is an oncologist? No? That’s why your observation that Burzynski (a biochemist) is NOT an oncologist, is irrelevant.
Do you have any proof to back up your remarkable claim:
“Against that we have an anonymous shill who takes every word of the Burzynski clinic and its supporters as Revealed Truth”?
No? That’s because you’re wrong about that just like the other issues I’ve listed above.
Mr. Chapman, you attempts at obfuscation of the issues, does not impress.
Peter Lipson: “Speech is best countered by more speech”

Share your comment:
facebook
linkedin
twitter

America, Land of the “Free Speech” and Home of the Brave; well, unless your #Forbes?

TheSkeptiCritic (@TheSkeptiCritic) tweeted at 6:29pm – 22 Apr 13:
http://t.co/8PjEPukjpP…
“@drpaulmorgan: @JamesBrewer @charlottechurch There will soon be a @BBCPanorama
#Burzynski

Or you can join in here

forbes.com/sites/peterlip…—
(@TheSkeptiCritic) April 22, 2013

TheSkeptiCritic (@TheSkeptiCritic) tweeted at 11:54pm – 22 Apr 13:
http://t.co/8PjEPukjpP
“@robertquickert: I wonder how many scientists consider SEC filings as proof” #Burzynski

You miss the point #Forbes

forbes.com/sites/peterlip—
(@TheSkeptiCritic) April 23, 2013

TheSkeptiCritic (@TheSkeptiCritic) tweeted at 12:22am – 23 Apr 13:
#Forbes #Censors Lipson”Speech is best countered by more speech”posts after I post David H. Gorski posts Peter is his “pal”
#Burzynski
#EPIC—
(@TheSkeptiCritic) April 23, 2013

TheSkeptiCritic (@TheSkeptiCritic) tweeted at 12:27am – 23 Apr 13:
https://t.co/DttIrMVCzh
#Forbes #Censors Peter Lipson “Speech is best countered by more speech” #Burzynski
►Streisand Effect
@BurzynskiMovie

twitter.com/TheSkeptiCriti…—
(@TheSkeptiCritic) April 23, 2013
Censorship in America
Burzynski: Cancer Is Serious Business, Part II (Part 2)
Eric Merola
@BurzynskiMovie
#Burzynski
Burzynski Clinic
United States Supreme Court
First Amendment
http://my.billofrightsinstitute.org/page.aspx?pid=472

Advertisements

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s